A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.

Ong, Jian Chun Matthew; Than, Hein; Tripathi, Sandeep; Gkitzia, Christina; Wang, Xiaojun

A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.

Ong, Jian Chun Matthew; Than, Hein; Tripathi, Sandeep; Gkitzia, Christina; Wang, Xiaojun.

Afiliación

Ong JCM; Novartis Singapore Pte. Ltd., Mapletree Business City, Singapore, Singapore.
Than H; Department of Haematology, Singapore General Hospital, Singapore, Singapore.
Tripathi S; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Gkitzia C; Novartis Pharma AG, Basel, Switzerland.
Wang X; Novartis Singapore Pte. Ltd., Mapletree Business City, Singapore, Singapore. nick-1.wang@novartis.com.

Cost Eff Resour Alloc ; 21(1): 34, 2023 May 31.

Article en En | MEDLINE | ID: mdl-37259074

Palabras clave

Allogeneic; Cost; Direct medical costs; Life year; QALY; Ruxolitinib; Transplant; cGVHD

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Cost Eff Resour Alloc Año: 2023 Tipo del documento: Article País de afiliación: Singapur Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google